3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
76
Gynecologic
75
Breast
75
Gastrointestinal
56
Head & Neck
25
Tumor-Agnostic
11
Genitourinary
10
Sarcoma
8
Dermatologic
7
Other solid neoplasm
6
CNS
4
Other neoplasm
2
Other hematologic neoplasm
2
Lymphoid
1
Endocrine
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Multiple Endocrine Neoplasia Type 2a
1
Lethal Congenital Contracture Syndrome 2
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Magnetic Resonance Spectroscopy
15
Specimen Handling
14
lutetium Lu 177 dotatate
13
Nivolumab
11
cabozantinib
10
Everolimus
9
pembrolizumab
8
gallium Ga 68 dotatate
7
Ipilimumab
6
Cisplatin
6
Carboplatin
6
Etoposide
5
trametinib
4
olaparib
4
lenvatinib
4
X-Rays
4
Lutetium-177
4
CTLA-4 Antigen
4
fluorodopa F 18
3
dabrafenib
3
cemiplimab
3
Surveys and Questionnaires
3
Phantoms, Imaging
3
Immunoglobulin G
3
Fluorodeoxyglucose F18
3
Disulfides
3
Cyclophosphamide
3
Blood Specimen Collection
3
177Lu-octreotide, DOTA(0)-Tyr(3)-
3
selpercatinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Paclitaxel
×
Endocrine
×
90 days
×
Clear all
NCT05142189
2026-04-14
LuCa-MERIT-1
BioNTech SE
Phase 1
Recruiting
320 enrolled